Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2016

Mulvey JJ, Nuovo GJ, Magro CM. Cutaneous, Purpuric Painful Nodules Upon Addition of Ibrutinib to RCVP Therapy in a CLL Patient: A Distinctive Reaction Pattern Reflecting Iatrogenic Th2 to Th1 Milieu Reversal. Am J Dermatopathol. 2016;38(7):492-8.

Sethi S, Haas M, Markowitz GS, D'Agati VD, Rennke HG, J Jennette C, et al. Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN. J Am Soc Nephrol. 2016;27(5):1278-87.

Gounden V, Zhao Z. Eltrombopag interference in routine chemistry testing. Ann Clin Biochem. 2016;53(Pt 5):611-4.

Pisapia DJ, Lavi E. VZV, temporal arteritis, and clinical practice: False positive immunohistochemical detection due to antibody cross-reactivity. Exp Mol Pathol. 2016;100(1):114-5.

Huong G, Olson LC, Rippis GE, Magro CM. An Index Case of Cutaneous Hodgkin Lymphoma and Review of the Literature. Am J Dermatopathol. 2016;38(10):739-43.

Gayvert KM, Dardenne E, Cheung C, Boland MR, Lorberbaum T, Wanjala J, et al. A Computational Drug Repositioning Approach for Targeting Oncogenic Transcription Factors. Cell Rep. 2016;15(11):2348-56.

Wike CL, Graves HK, Wason A, Hawkins R, Gopalakrishnan J, Schumacher J, et al. Excess free histone H3 localizes to centrosomes for proteasome-mediated degradation during mitosis in metazoans. Cell Cycle. 2016;15(16):2216-2225.

Jain T, Williams R, Liechty B, Chen LA. Vertebral Metastasis as the Initial Manifestation of Colon Cancer. ACG Case Rep J. 2016;3(4):e122.

Locatelli SL, Careddu G, Inghirami G, Castagna L, Sportelli P, Santoro A, et al. The novel PI3K-δ inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest. Leukemia. 2016;30(12):2402-2405.

Patel KR, Phillips DJ, Leibowitz JM, Scognamiglio T, Banuchi VE, Kuhel WI, et al. Value within otolaryngology: Assessment of the cost-utility analysis literature. World J Otorhinolaryngol Head Neck Surg. 2016;2(1):28-37.